Several laboratories, including ours, have addressed this critical question in preclinical studies and, while the sequence of administration and dosing appears to be dependent on respective mouse models, combined treatment of anti-OX40 with checkpoint blockade has shown greater anti-tumor activity33,34,43. Here, TNFRSF4 is linked to neoplasm.